ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene, others back start-up Sapience

by Michael McCoy
July 18, 2016 | APPEARED IN VOLUME 94, ISSUE 29

Sapience Therapeutics has raised $22.5 million in a Series A financing round lead by Eshelman Ventures and including Celgene, TaiAn Technologies, and Healthlink Capital. Sapience is based on ST-36, a peptide-based drug that was licensed from Columbia University. Sapience says ST-36 selectively targets a protein that promotes the growth of many types of tumors. Its initial target is glioblastoma, a brain cancer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment